We are monitoring the impact of COVID-19 on North America Next Generation Antibody Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5224
Share on
Share on

North America Next-Generation Antibody Therapeutics Market Research Report - Segmented By Therapeutics, Technology & Country (The United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, Growth, Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 5224
Pages: 145

North America Next-Generation Antibody Therapeutics Market Size (2021 to 2026):

The size of the North America Next-Generation Antibody Therapeutics Market is estimated to worth USD 3.02 billion by 2026 from USD 1.53 billion in 2021. It is expected to grow at a CAGR of 14.5% from 2021 to 2026.

Increased number of pharma, biopharma, and biotechnology companies are flourishingly investing in enhancing next-gen therapeutic antibodies opposite to autoimmune diseases, inflammatory disorders, and cancers, increasing utilization of antibody-drug conjugate (ADC) is the present trend over the market having positive vibrations for the market growth. Also, novel drug discoveries, a considerable number of government steps for the market growth, and growing acceptance for the drug discoveries are to surge the growth. In the U.S, an estimation of 1,735,350 new cancer cases is diagnosed, and 609,640 people lose their life due to this disease, according to the National Cancer Institute in 2018. Cancer accounts for 13% of the deaths every year, and a 70% surge in cancer occurrence is predicted for the next couple of years. Rising elder people population is projected to increase from 12% to 22% from 2015 to 2022 during the period.

Strict government regulations for the approval of antibody therapies are obstructing the market. High costs associated with therapies and the time required for the research and development activities are likely to hinder the market growth in the region.

This research report on the North America Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories

By Therapeutics:

  • Oncology
  • Autoimmune/Inflammatory Diseases

By Technology:

  • Antibody-Drug Conjugates (ADCs)
  • Bispecific Antibodies (BsAbs)
  • Fc Engineered Antibodies
  • Antibody Fragments
  • Antibody-like Proteins
  • Biosimilar Antibody Products

By Country:

  • The United States
  • Canada
  • Rest of North America

Regional Analysis:

North America dominates the global next-generation antibody therapeutics market with the largest market share. The United States is the leader in the North American market. North America is ruling the next-generation antibody therapeutics market over the period in 2019. Factors like huge funds and investments for research and development and the rise in the aging population boost the growth in the market. The United States is leading the market of this region, followed by Canada. Regular increase of chronic diseases like cancer, asthma, and COPD and augment of old people population is propelling the market. Rising healthcare expenditure in developed and developing countries, advancements in technology are one of the key factors fueling the growth. For example, the development of glycoengineered antibody BsAbs and ADC technologies enlarged the application areas of antibody therapies. The robust appearance of established key players in the region and firmly developed life sciences research infrastructure are propelling the market growth. Canada is counted upon to have rapid growth in the market with the highest share. The government's support plays a vital role in research related to the next-gen antibody therapy, and extensive applications of those therapies are ascribed to bolster the market growth.

Key players dominating the North America Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.

1.Introduction           

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions                

2. Research Methodology                    

                2.1 Introduction        

                2.2 Research Phases                      

         2.2.1 Secondary Research           

         2.2.2 Primary Research 

         2.2.3 Econometric Modelling      

         2.2.4 Expert Validation  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview                

                3.1 Executive Summary                

                3.2 Key Inferences  

                3.3 Epidemology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints                    

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation

                5.1 Technology                 

         5.1.1 Introduction           

         5.1.2 Antibody-Drug Conjugates (ADCs)               

         5.1.3 Bispecific Antibodies (BsAbs)          

         5.1.4 Fc Engineered Antibodies 

         5.1.5 Antibody Fragments and Antibody-like Proteins    

         5.1.6 Biosimilar Antibody Products          

         5.1.7 Y-o-Y Growth Analysis, By Technology        

         5.1.8 Market Attractiveness Analysis, By Technology      

         5.1.9 Market Share Analysis, By Technology        

                5.2 Therapeutic Application 

         5.2.1 Introduction           

         5.2.2 Oncology 

         5.2.3 Autoimmune/Inflammatory Diseases         

         5.2.4 Y-o-Y Growth Analysis, By Therapeutic Application               

         5.2.5 Market Attractiveness Analysis, By Therapeutic Application             

         5.2.6 Market Share Analysis, By Therapeutic Application               

6. Geographical Analysis

               6.1 Introduction        

         6.1.1 Regional Trends    

         6.1.2 Impact Analysis     

         6.1.3 Y-o-Y Growth Analysis        

  6.1.3.1 By Geographical Area

  6.1.3.2 By Technology

  6.1.3.3 By Therapeutic Application

         6.1.4  Market Attractiveness Analysis     

  6.1.4.1 By Geographical Area

  6.1.4.2 By Technology

  6.1.4.3 By Therapeutic Application

        6.1.5  Market Share Analysis      

  6.1.5.1 By Geographical Area

  6.1.5.2 By Technology

  6.1.5.3 By Therapeutic Application

                6.2 United States     

                6.3 Canada  

7. Strategic Analysis                

                7.1 PESTLE analysis  

         7.1.1 Political     

         7.1.2 Economic 

         7.1.3 Social         

         7.1.4 Technological         

         7.1.5 Legal          

         7.1.6 Environmental       

                7.2 Porter’s Five analysis       

         7.2.1 Bargaining Power of Suppliers        

         7.2.2 Bargaining Power of Consumers    

         7.2.3 Threat of New Entrants     

         7.2.4 Threat of Substitute Products and Services              

         7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                 

                8.1 Roche    

         8.1.1 Overview 

         8.1.2 Product Analysis   

         8.1.3 Financial analysis  

         8.1.4 Recent Developments       

         8.1.5 SWOT analysis       

         8.1.6 Analyst View          

                8.2 Seattle Genetics

                8.3 Takeda  

                8.4 Dyax Corp.                  

                8.5 Immunogen        

                8.6 Amgen, Inc.         

                8.7 Biogen   

                8.8 Kyowa Hakko Kirin Co., Ltd.                 

                8.9 AstraZeneca        

                8.10 Pfizer, Inc.                

9. Competitive Landscape                    

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, Collaborations, and Joint Ventures  

                9.4 New Product Launches  

10. Market Outlook and Investment Opportunities                  

Appendix                    

                a) List of Tables                

                b) List of Figures       

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of product type market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Next-Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  2. North America Antibody-Drug Conjugates (ADCs) Market By Region, From 2021 to 2026 ( USD Billion )
  3. North America Bispecific Antibodies (BsAbs) Market By Region, From 2021 to 2026 ( USD Billion )
  4. North America Fc Engineered Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  5. North America Antibody Fragments and Antibody-like Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  6. North America Biosimilar Antibody Products Market By Region, From 2021 to 2026 ( USD Billion )
  7. North America Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  8. North America Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  9. North America Autoimmune/Inflammatory Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  10. United States Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  11. United States Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )
  12. Canada Next Generation Antibody Therapeutics Market By Technology, From 2021 to 2026 ( USD Billion )
  13. Canada Next Generation Antibody Therapeutics Market By Therapeutic Application, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample